The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy

Gynecologic Oncology

Volumn 78, Issue 1, 2000, Pages 43-46

  Markman, Maurie ^a,b   Kennedy, Alexander ^a,b   Webster, Kenneth ^a,b   Peterson, Gertrude ^a,b   Kulp, Barbara ^a,b   Belinson, Jerome ^a,b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; ONDANSETRON; PACLITAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CYTOTOXICITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; PRIORITY JOURNAL; TREATMENT PLANNING; VOMITING;

EID: 0033922573     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2000.5824     Document Type: Article

References (24)

1. Grunberg SM, Hesketh PJ: Control of chemotherapy-induced emesis. N Engl J Med 329:1790-1796, 1993
2. Harvey VJ, Evans BD, Mitchell PLR, Mak D, Neave LM, Langley GB, Dickson DSP: Reduction of carboplatin induced emesis by ondansetron. Br J Cancer 63:942-944, 1991
3. Smith DB, Newlands ES, Rustin GJS, Begent RHJ, Howells N, McQuade B, Bagshawe KD: Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet 338:487-490, 1991
4. Smyth JF, Coleman RE, Nicolson M, Gallmeier WM, Leonard RCF, Cornbleet MA, Allan SG, Upadhyaya BK, Bruntsch U: Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? Br Med J 303:1423-1426, 1991
5. Roila F, Tonato M, Cognetti F, Cortesi E, Favalli G, Marangolo M, Amadori D, Bella MA, Gramazio V, Donati D, Ballatori E, Del Favero A: Prevention of cisplatin-induced emesis: A double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9:675-678, 1991
6. BeckTM, Ciociola AA, Jones SE, Harvey WH, Tchekmedyian NS, Chang A, Galvin D, Hart NE, Ondansetron Study Group: Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 118:407-413, 1993
7. Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, Hainsworth J, Bushnell W, Friedman C: Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: A multicenter, double-blind, randomized parallel study. J Clin Oncol 16:754-760, 1998
8. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J: Control of carboplatin-induced emesis with a fixed low dose of granisetron (0.5 mg) plus dexamethasone. Gynecol Oncol 60:435-437, 1996
9. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J: Low dose oral granisetron (1 mg) plus intravenous dexamethasone: Efficacy in gynecologic cancer patients receiving carboplatin-based chemotherapy. Gynecol Oncol 71:113-115, 1998
10. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J: Low-dose intravenous ondansetron (8 mg) plus dexamethasone: An effective regimen for the control of carboplatin-induced emesis. J Cancer Res Clin Oncol 123:224-226, 1997
11. Rose WC, Schurig JE: Preclinical antitumor and toxicologic profile of carboplatin. Cancer Treat Rev 12(Suppl A): 1-19, 1985
12. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MM, Harrap KR: Early clinical studies with c/s-diammine-1, 1-cyclobutane dicarboxylate platinum(II). Cancer Chemother Pharmacol 9:140-147, 1982
13. Martin M, Diaz-Rubio E, Sanchez A, Almenarez J, Lopez-Vega JM: The natural course of emesis after carboplatin treatment. Acta Oncol 29:593-595, 1990
14. Smith DB, Rustin GJS, Howells N, Lambert HE, McQuade B, for the North Thames Ovary Group: A phase II study of ondansetron as antiemetic prophylaxis in patients receiving carboplatin for advanced ovarian cancer. Ann Oncol 2:607-608, 1991
15. Gridelli C, Incoronato P, Airoma G, Pepe R, Arpinelli F, Bianco AR: Ondansetron in the prophylaxis of nausea and vomiting induced by carboplatin combination chemotherapy. Eur J Cancer 29A:651, 1993
16. du Bois A, McKenna CJ, Andersson H, Lahousen M, Kitchener H, Pinter T, Capstick V, Wilkinson JR: A randomised, double-blind, parallel-group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis induced by carboplatin chemotherapy. Oncology 54:7-14, 1997
17. Tanneberger S, Lelli G, Martoni A, Piana E, Pannuti F: The antiemetic efficacy and the cost-benefit ratio of ondansetron calculated with a new approach to health technology assessment (Real Cost-Benefit Index). J Chemother 4:326-331, 1992
18. Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, Ritter H, Friedman C, Fitts D, on behalf of the Granisetron Study Group. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 13:1242-1248, 1995
19. Ozols RF, Bundy BN, Fowler J, Clarke-Pearson D, Mannel R, Hartenbach EM, Baergen R: Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial (GOG 158). [abstract] Proc Am Soc Clin Oncol 18:356a, 1999
20. Zanotti KM, Belinson JL, Kennedy AW, Webster KD, Markman M: The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol 74:272-277, 1999
21. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J: Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: The Cleveland Clinic experience. Semin Oncol 24(Suppl 15):26-29, 1997
22. Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF: Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol 8:611-614, 1997
23. Micha JP, Rettenmaier MA, Dillman R, Fraser P, Birk C, Brown JV: Single-dose dexamethasone paclitaxel premedication. Gynecol Oncol 69: 122-124, 1998
24. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J: Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reactions. J Clin Oncol 15:3517, 1997